Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02489994
Other study ID # DHF15911
Secondary ID
Status Active, not recruiting
Phase N/A
First received June 25, 2015
Last updated March 17, 2016
Start date October 2014
Est. completion date October 2016

Study information

Verified date March 2016
Source Syneron Medical
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Clinical Study to Evaluate the Performance of the ePrime System for the Treatment of Cellulite.


Description:

Up to 60 healthy adult volunteers seeking cellulite treatment, females of 25 to 60 years of age, from multiple investigational sites.

This is an open-label, multi-center study. Subjects in this study will receive a single subcutaneous treatment with the ePrime device in one treatment session according to the study protocol.

Prior to treatments, tissue to be treated will be injected with tumescence or local dermal infiltration solution according to the protocol. Subjects will return for follow‐up (FU) visits at: 1 week, 1 month, 3 months and 6 months following the treatment.

Methodology described in protocol to evaluate efficacy of treatments will be carried out at each visit.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 51
Est. completion date October 2016
Est. primary completion date August 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 25 Years to 60 Years
Eligibility Inclusion Criteria:

1. Subjects seeking treatment of cellulite in the upper thighs and buttocks areas.

2. Subject have cellulite stage II or III as graded using Nurnberger-Muller scale clasification (Appendix III)

3. Healthy female subjects ages 25 to 60 years of age

4. Informed consent process completed and subject signed consent

5. Willing to receive the proposed ePrime treatment and follow-up protocol

6. Not pregnant or lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence)

7. Willing to have photographs taken of the treated areas to be used de-identified in evaluations, publications and presentations

Exclusion Criteria:

1. Subject had surgery or any other procedure for cellulite in the last 6 months

2. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding

3. Known allergy to lidocaine or epinephrine or antibiotics

4. Active malignancy or history of malignancy in the past 5 years

5. Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator

6. Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e. any disease state that in the opinion of the Physician would interfere with the anesthesia, treatment, or healing process)

7. Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion)

8. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications

9. Suffering from hormonal imbalance, whether related to thyroid, pituitary, or androgen

10. History of significant lymphatic drainage problems

11. History of cancer which required lymph node biopsy or dissection

12. Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions, hidradenitis, or dermatitis of the treatment area prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course

13. History of keloid scarring, abnormal wound healing and / or prone to bruising

14. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders

15. Use of isotretinoin (Accutane®) within 6 months of treatment or during the study

16. Subject on systemic corticosteroid therapy 6 months prior to and throughout the course of the study

17. Dysplastic nevi in the area to be treated

18. Participation in a study of another device or drug within 3 month prior to enrollment or during this study, if treatments of cellulite were involved

19. Subject has palpable lymphadenopathy at any visit. Standard palpation techniques will be used

20. Subjects with history of severe edema

21. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
ePrime
The main intent of the ePrime for cellulite is to utilize a minimally-invasive approach to directly deliver RF energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.

Locations

Country Name City State
United States Girish Munavalli Charlotte North Carolina
United States David Goldberg Hackensack New Jersey
United States Bowes Leyda Miami Florida
United States Macrene Alexiades New York New York

Sponsors (1)

Lead Sponsor Collaborator
Syneron Medical

Country where clinical trial is conducted

United States, 

References & Publications (2)

Rawlings AV. Cellulite and its treatment. Int J Cosmet Sci. 2006 Jun;28(3):175-90. doi: 10.1111/j.1467-2494.2006.00318.x. — View Citation

Rossi AB, Vergnanini AL. Cellulite: a review. J Eur Acad Dermatol Venereol. 2000 Jul;14(4):251-62. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement in cellulite compared to baseline for the upper thighs and buttocks, as assessed by blinded evaluation of clinical photographs Evaluate the efficacy of a single dermal and subcutaneous treatment with ePrime for the upper thighs and buttocks cellulite as assessed by blinded evaluators at 3 months post treatment visit. Baseline and 3 months post treatment visit No
Secondary Improvement in cellulite compared to baseline for the upper thighs and buttocks, as assessed by blinded evaluation of clinical photographs Evaluate the efficacy of a single dermal and subcutaneous treatment with ePrime for the upper thighs and buttocks cellulite as assessed by blinded evaluators at 6 months post treatment visit. Baseline and 6 months post treatment visit No
Secondary Number of Participants with Adverse Events evaluate the safety of a single dermal and subcutaneous treatment with ePrime for the upper thighs and buttocks cellulite at 1 week post treatment, 1 month, 3 and 6 months following the treatment. day 0 up to 7 months Yes
Secondary Improvement in cellulite compared to baseline Improvement in cellulite compared to baseline, as assessed by study investigators, using Nurnberger-Muller scale at 1 month, 3 and 6 months post treatment visit. Baseline, 1 month, 3 and 6 months post treatment visit. No
Secondary Investigator satisfaction - by questionnaire Evaluate Investigator satisfaction at 1, 3, and 6 months post-treatment visit, using a satisfaction scale 1, 3, and 6 months post-treatment visit No
Secondary Subject satisfaction - by questionnaire Evaluate subject satisfaction at 1, 3, and 6 months post-treatment visit, using a satisfaction scale 1, 3, and 6 months post-treatment visit No
See also
  Status Clinical Trial Phase
Completed NCT03550157 - Structural Changes of Subcutaneous Tissue by Ultrasonographies in Patients After Treatment With PnKCelulitis® Program
Completed NCT03078647 - Profound Dermal and SubQ Cartridges for the Treatment of Cellulite N/A
Suspended NCT05441917 - Phototherapy and Radiofrecuency for Cellulite N/A
Completed NCT02942160 - EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite) Phase 2
Completed NCT01209767 - Cryolipolysis and Subcision for Treatment of Cellulite N/A
Completed NCT01702259 - Study of the Effect of Low Level Laser Light Therapy on Reducing the Appearance of Cellulite in the Thighs and Buttocks. N/A
Completed NCT04580303 - CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques Phase 2
Completed NCT05358847 - Treatment for Cellulite Appearance N/A
Terminated NCT04209530 - Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women Phase 2
Completed NCT05064761 - Safety and Effectiveness of Poly-l-lactic Acid (PLLA) for the Improvement in Appearance of Cellulite N/A
Completed NCT03329989 - Safety and Effectiveness of EN3835 in the Treatment of EFP in Women Phase 2
Completed NCT04170296 - Real World CCH Study in Adult Females With Cellulite Phase 3
Completed NCT04419454 - Retrospective Evaluation of Cellulite of Laxity Treatment Using Body Tite
Completed NCT05199506 - Study to Evaluate the Safety and Effectiveness of the RAP Device for the Improvement in the Appearance of Cellulite N/A
Completed NCT05836779 - A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2) Phase 2
Completed NCT05026216 - To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Qwo, for the Treatment of Mild to Moderate Cellulite. Phase 4
Completed NCT00399854 - Evaluation of the Efficacy of Endermologie in Treatment of Cellulite and Body Contouring Phase 4
Completed NCT00947414 - Cellulite and Extracorporeal Shock Wave N/A
Completed NCT05419505 - Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks Phase 2
Completed NCT03981198 - Proof of Concept (POC) Study of the Soliton Rapid Acoustic (RAP) for the Treatment of Cellulite N/A